Ophthalmology Times Newsletter

To view this email as a web page, click here.

Breaking down the dorzolamide shortage

The supply of dorzolamide, long a first-line glaucoma therapy used alone or in fixed combination with timolol, has recently proven unreliable, writes Nathan M. Radcliffe, MD. Here’s what we can do about it.

Learn more

FDA approves aflibercept prefilled syringe injection

The only anti-VEGF approved to treat four retinal conditions with a single dose strength prefilled syringe, aflibercept (Eylea, Regeneron), also is offered in multiple dosing intervals, giving doctors flexibility to address patients’ individual needs.

Find out

LHON gene therapy: Deciphering phase III data

Phase III studies of a gene therapy for Leber hereditary optic neuropathy have generated some unexpected positive findings. There is biologic plausibility to explain the data, according to Robert C. Sergott, MD.

Continue

Getting started with TECNIS Symfony^® IOL

TECNIS Symfony^® IOL combines two complimentary and proprietary technologies to provide continuous high-quality vision at all distances.

Download the Getting Started Guide now.

Flying solo poses challenges, flexibility and support vital

Ophthalmology grabs Wall Street's attention

Set expectations for glaucoma patients undergoing cataract surgery

(VIDEO) OSPREY trial aids fluid assessment

Be sure to check out Targeting Anterior Uveitis: A Focus on Iontophoresis and Other Advanced Technologies, a sponsored CME supplement from MedEdicus.

Learn more

JOB OPPORTUNITIES

VT - University of Vermont

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.